Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
Aneta Szudy‐Szczyrek(Medical University of Lublin), Marek Hus(Medical University of Lublin), Radosław Mlak(Medical University of Lublin), Michał Szczyrek(Medical University of Lublin), Jacek Sompor(Medical University of Lublin), Iwona Homa‐Mlak(Medical University of Lublin), Agata Filip(Medical University of Lublin), Teresa Małecka‐Massalska(Medical University of Lublin), Aleksandra Nowaczyńska(Medical University of Lublin), Szymon Zmorzyński(Medical University of Lublin), Michał Mielnik(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Kinga Kuśmierczuk(Medical University of Lublin)
Cited by 23
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70